Summary & Overview
CPT 90585: Tuberculosis Live Vaccine, Intradermal Administration
CPT code 90585 denotes a live vaccine product administered through the skin to protect against tuberculosis. This code identifies intradermal delivery of a live attenuated mycobacterial vaccine used in preventive public health and clinical immunization programs. Nationally, accurate coding for TB vaccination supports surveillance, public health reporting, and appropriate claims adjudication for preventive services.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise understanding of the clinical context for CPT code 90585, the typical service setting, and which major payers are relevant for coverage and claims processing. The publication summarizes common billing modifiers (provided), typical sites of service, and practical coding considerations for vaccine administration claims.
The report covers benchmarks and policy context relevant to national payers, outlines areas where code-specific guidance commonly matters (vaccine product identification, administration route, and site of service), and highlights where additional payer-specific rules or prior authorization requirements may appear. Data not available in the input (such as associated taxonomies, ICD-10 diagnoses, and related codes) are noted as missing.
Billing Code Overview
CPT code 90585 represents a live vaccine product administered through the skin to protect against tuberculosis (TB). The service involves delivery of a live attenuated mycobacterial vaccine intended to stimulate protective immunity against tuberculosis.
Service type: Vaccine administration (intradermal live vaccine)
Typical site of service: Outpatient clinic, public health clinic, or other ambulatory care settings
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 28-year-old immigrant presents to a public health clinic for tuberculosis (TB) screening and prevention. The patient has no history of prior TB vaccination or documented Bacillus Calmette–Guérin (BCG) vaccine and is scheduled for intradermal administration of a live TB vaccine product. Pre-procedure documentation includes clinical history, allergy review, informed consent, and verification of vaccine lot number and expiration. The procedure is performed in an outpatient clinic or public health department exam room. The provider — typically a nurse or physician trained in vaccine delivery — prepares the intradermal site (usually the volar aspect of the forearm), administers the vaccine using aseptic technique, records the administration in the patient’s chart and immunization registry, and provides post-vaccination guidance on expected local reactions and when to return for evaluation. If immediate adverse reaction occurs, emergency equipment and protocols are available on site. Billing uses 90585 for the live intradermal TB vaccine product administered through the skin; documentation should include vaccine name, dose, route (intradermal), site of administration, lot number, manufacturer, and the identity of the administering clinician.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no other modifier applies and full service is rendered |